TransThera Sciences (Nanjing) (HKG:2617) completed the filing for the conversion of nearly 45 million domestic shares into Hong Kong-listed shares with the China Securities Regulatory Commission, a Monday bourse filing showed.
Shares of the clinical-stage biopharmaceutical company were down 3% in Tuesday afternoon trading.
The company will apply to the Hong Kong bourse's Listing Committee for approval to list and deal in the shares.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments